CN102827937A - Primer and probe for detecting relative fusion genes of leukemia and kit of primer and probe - Google Patents
Primer and probe for detecting relative fusion genes of leukemia and kit of primer and probe Download PDFInfo
- Publication number
- CN102827937A CN102827937A CN2012103275473A CN201210327547A CN102827937A CN 102827937 A CN102827937 A CN 102827937A CN 2012103275473 A CN2012103275473 A CN 2012103275473A CN 201210327547 A CN201210327547 A CN 201210327547A CN 102827937 A CN102827937 A CN 102827937A
- Authority
- CN
- China
- Prior art keywords
- seq
- sample
- pcr
- primer
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to detection of genotypes, in particular to a primer and a probe for detecting relative fusion genes of leukemia and a kit of the primer and the probe. The kit can qualitatively detect quantity of BCR-ABL, AML1-ETO and PML-RARa of the relative fusion genes of the leukemia in human marrow specimens so as to instruct clinical diagnosis and pharmacy of the leukemia.
Description
Technical field
The present invention relates to genotypic detection, specifically, relate to a kind of primer and probe and test kit thereof that detects the relevant fusion gene of white blood disease.
Background technology
White blood disease (Leukemia) is a malignant tumor of hematopoiesis system; It is characterized in that one or more hemocyte generation malignant proliferations in the hemopoietic systems such as marrow, lymphoglandula; And respectively organize internal organs in the infiltration body, and cause the normal hematopoiesis histocyte to be suppressed, produce various symptoms.Often with heating, hemorrhage, anaemia, liver, spleen, the enlargement of lymph node is characteristics greatly clinically for white blood disease.White blood disease generally can be divided into acute leukemia (AL) and chronic leukemia (CL) by natural history and cell development degree; According to leukemia cell's form and biochemical character, can be divided into acute lymphoblastic leukemia (ALL), acute nonlymphocytic leukemia (ANLL), chronic myelocytic leukemia (CML), leukemia chronic myelo-monocytic (CMML) etc. again.
White blood disease is one of domestic ten big malignant tumours occurred frequently, and its sickness rate is 2.76/10 ten thousand populations, and China estimates at 50,000 above patients, and leukaemic's quantity increases just year by year.Though leukemic sickness rate is arranged the 6th in tumor incidence, in the M & M of children and teenager's malignant tumour, all account for the 1st.
Recent clinical studies shows that there are some chromosome aberration in most of white blood disease and lymphoma, like transposition, disappearance, insertion etc.Can produce new fusion gene under most of situation during these chromosome translocation distortion, these fusion genes can be used as and are used to diagnose dissimilar white blood disease and lymphadenomatous molecular marker.Dissimilar leukemia chemotherapies is different with the scheme of radiotherapy.So, these molecule markers are carried out check and analysis help confirming of regimen and analyze prognosis.Therefore, the white blood disease of World Health Organization's issue in 2000 and Lymphoma Diagnosis standard detect fusion gene after the chromosome translocation as one of most important index.
It is the most deep part of studying in each quasi-leukemia that the BCR-ABL fusion gene is expressed, and BCR-ABL is relevant with the chromosomal formation in Philadelphia (Ph), is modal chromosome abnormalty in the white blood disease.Can detect this Ph karyomit(e) among the CML patient of about 90%-95%.The molecular basis that Ph karyomit(e) forms is to form the BCR-ABL fusion gene on No. 9 bcr genes on c-ab1 group translocation to 22 karyomit(e) on the karyomit(e), and promptly t (9; 22) (q34; Q11) transposition.Clinically detect Ph karyomit(e) as the CML classification diagnosis according to, therapeutic evaluation, and the reliability index of the detection of minimal residual disease and prognosis evaluation.In addition, what deserves to be mentioned is, in CML; The CML patient that some Ph karyomit(e) is negative, its BCR-ABL fusion gene is also positive, and this possibly be that a part of Ph karyomit(e) is difficult for seeing clearly; According to statistics; In patient CML, the positive rate of BCR-ABL fusion gene is 99%, and this more cytogenetic method of detection that molecular level also is described is more responsive.In addition, in acute lymphoblastic leukemia, also exist t (9; 22) (q34; Q11) transposition forms the BCR-ABL fusion gene.
T (15; 17) (q22; Q12-21) transposition is shown among the ANLL of 10%-15%, is found among the APL more than 90%, becomes the special sign of APL, and transposition produces the PML-RARa fusion gene.PML gene (promyelocytic leukemia gene) is positioned at karyomit(e) No. 15; Total length 50kb; Its various structure territory is by different exons codings, exons 1 coding proline(Pro) active region, exon 2 coding zinc fingers; Exon 3 coding and Dimerized relevant spirane structure, exon 4-6 coding a helical region.The PML-RARa fusion gene can be used as the molecular indexes of the small Restzustand of monitoring white blood disease; It is detected help further to understand the dynamics that the leukaemic is alleviated leukemia cell in the body of back; Obtain a new standard of alleviating fully of confirming from molecular level, thereby can make correct evaluation, in time adjust regimen the clinical treatment reaction; Alleviate patient's economical load, reduce the unnecessary misery that chemotherapy caused simultaneously.
T (8; 21) (q22; Q22) be modal chromosome translocation among the AM, incidence can be up to 20%-40%, and 90% is shown in the M2b type white blood disease, and transposition causes the generation of AML1-ETO fusion gene.The AML1-ETO fusion gene positive is prognosis bona's a sign, and it is alleviated (CR) rate fully and can reach 90%, 5 year long-term DFS and can reach 50%-70%.Adopt the chromosome karyotype analysis result to detect the result that this fusion gene obtains contradiction sometimes, it is carried out fluorescent quantitation detect and to carry out classification to patient's the state of an illness, thereby carry out judgement of prognosis more accurately and recurrence detection.
At present leukemic inspection is mainly contained, hemogram checking, examination of bone marrow smear, blood biochemistry checking etc., but these do not check to fusion gene that all the resultant error scope of acquisition is also bigger.The method that detects fusion gene at present mainly comprises fluorescence in situ hybridization technique (FISH), PCR and gene chip etc.But these methods exist defectives such as poor accuracy, complicated operation, the clinical application difficulty.
In order to help clinicians accurately and timely to detect leukemia fusion gene, auxiliary confirm to be correlated with chemotherapy regimen and recurrence detection; The present invention is from China's actual conditions; Developed the relevant fusion gene detection kit of white blood disease; The RNA amount of BCR-ABL, AML1-ETO and PML-RARa in the relevant fusion gene of white blood disease in this test kit ability qualitative detection people bone marrow prepare, thus white blood disease clinical diagnosis and medication instructed.
Summary of the invention
The present invention relates to a kind of primer that detects the relevant fusion gene of white blood disease and probe, test kit.
In order to accomplish the object of the invention, the technical scheme of employing is:
The present invention relates to a kind of primer and probe that detects the relevant fusion gene of white blood disease, wherein, the nucleotides sequence of said primer and probe is classified as:
(1) primer and the probe that are used to detect the BCR-ABL fusion gene are: by the upstream primer F1 shown in the SEQ ID NO:1; By the upstream primer F2 shown in the SEQ ID NO:2; By the upstream primer F3 shown in the SEQ ID NO:3, by the downstream primer shown in the SEQ ID NO:4, by the probe shown in the SEQ ID NO:5; Wherein 5 ' of the nucleotide sequence shown in SEQ ID NO:5 end has the Fam mark, and 3 ' end has the Tamara mark;
(2) primer and the probe that are used to detect the PML-RARa fusion gene are: by the upstream primer F1 shown in the SEQ ID NO:6; By the upstream primer F2 shown in the SEQ ID NO:7; By the upstream primer F3 shown in the SEQ ID NO:8, by the downstream primer shown in the SEQ ID NO:9, by the probe shown in the SEQ ID NO:10; Wherein 5 ' of the nucleotide sequence shown in SEQ ID NO:10 end has the Fam mark, and 3 ' end has the Tamara mark;
(3) primer and the probe that are used to detect the AML1-ETO fusion gene are: by the upstream primer F1 shown in the SEQ ID NO:11; By the downstream primer shown in the SEQ ID NO:12; By the probe shown in the SEQ ID NO:13; Wherein 5 ' of the nucleotide sequence shown in SEQ ID NO:13 end has the Fam mark, and 3 ' end has the Tamara mark.
The invention still further relates to a kind of primer and the test kit of probe that detects the relevant fusion gene of white blood disease, the consisting of of described test kit: described test kit comprises nucleic acid amplification reagent, reference substance and reference article, and wherein, described nucleic acid amplification reagent comprises:
Table 1:
Sequence number | Component | Major ingredient in the component |
1 | Detect the RT-PCR reaction solution 1 of BCR-ABL fusion gene | Primer, probe, dNTPs, buffer; |
2 | Detect the RT-PCR reaction solution 2 of PML-RARa fusion gene | Primer, probe, dNTPs, buffer; |
3 | Detect the RT-PCR reaction solution 3 of AML1-ETO fusion gene | Primer, probe, dNTPs, buffer; |
4 | RT confidential reference items PCR reaction solution | Primer, probe, dNTPs, buffer; |
5 | With reference to article PCR reaction solution | Primer, probe, dNTPs, buffer; |
6 | Mixed enzyme solution I | RT enzyme, Taq enzyme, UNG enzyme; |
7 | Mixed enzyme solution II | Taq enzyme, UNG enzyme. |
First optimal technical scheme of test kit of the present invention is:
Contain in the RT-PCR reaction solution 1 of detection BCR-ABL fusion gene: 5 * Buffer liquid, 5 μ l; Each 0.25 μ l of the dNTPs of 10mmol/L; Each 0.12 μ l of the SEQ ID NO:1 of 50 μ mol/L~SEQ ID NO:5; 50 μ mol/L SEQ ID NO:50.1 μ l complement to 8 μ l with process water;
Contain in the RT-PCR reaction solution 2 of detection PML-RARa fusion gene: 5 * Buffer liquid, 5 μ l; Each 0.25 μ l of the dNTPs of 10mmol/L; Each 0.12 μ l of the SEQ ID NO:6 of 50 μ mol/L~SEQ ID NO:10; 50 μ mol/L SEQ ID NO:100.1 μ l complement to 8 μ l with process water;
The primer and the probe that are used for detecting the AML1-ETO fusion gene are for containing: 5 * Buffer liquid, 5 μ l; Each 0.25 μ l of the dNTPs of 10mmol/L; Each 0.12 μ l of the SEQ ID NO:11 of 50 μ mol/L~SEQ ID NO:12; 50 μ mol/LSEQ ID NO:130.1 μ l complement to 8 μ l with process water;
Contain in the RT confidential reference items PCR reaction solution: 5 * Buffer liquid, 5 μ l; Each 0.25 μ l of the dNTPs of 10mmol/L; Each 0.12 μ l of the SEQ ID NO:14 of 50 μ mol/L~SEQ ID NO:16,50 μ mol/L SEQ ID NO:160.1 μ l complement to 8 μ l with process water; Wherein, By the upstream primer shown in the SEQ ID NO:14, by the downstream primer shown in the SEQ ID NO:15, by the probe shown in the SEQ ID NO:16; Wherein 5 ' of the nucleotide sequence shown in SEQ ID NO:16 end has the Fam mark, and 3 ' end has the Tamara mark;
With reference to containing in the article PCR reaction solution: 5 * Buffer liquid, 5 μ l; Each 0.25 μ l of the dNTPs of 10mmol/L; Each 0.12 μ l of the SEQ ID NO:17 of 50 μ mol/L~SEQ ID NO:18,50 μ mol/L SEQ ID NO:16,0.1 μ l complements to 8 μ l with process water; Wherein, by the upstream primer shown in the SEQ ID NO:17, by the downstream primer shown in the SEQ ID NO:18.
Second optimal technical scheme of test kit of the present invention is:
Table 2:
Sequence number | Component | Major ingredient in the component |
8 | Negative control | Process water; |
9 | Positive control 1 | Cell lysate; |
10 | Positive control 2 | The plasmid mixed solution. |
Contain K562, NB4 and Kasumi cell lysate in the described positive control 1, concentration is 2.5 * 103cells/ml; Described positive control 2 is for containing the segmental four kinds of plasmids of BCR-ABL, PML-RARa, AML1-ETO and abl gene purpose respectively, and its nucleotide sequence is respectively SEQ ID NO:19~SEQ ID NO:27, and concentration is 1pg/ml.
Wherein, the K562 cell lysate is that BCR-ABL fusion gene male K562 cell lysate, NB4 cell lysate PML-RARa fusion gene male NB4 cell lysate, Kasumi cell lysate are AML1-ETO fusion gene male Kasumi cell lysate.
The 3rd optimal technical scheme of test kit of the present invention is:
Table 3:
Sequence number | Component | Major ingredient in the component |
11 | With reference to article 1:1 * 10 6copies | Plasmid liquid; |
12 | With reference to article 2:1 * 10 5copies | Plasmid liquid; |
13 | With reference to article 3:1 * 10 4copies | Plasmid liquid; |
14 | With reference to article 4:1 * 10 3copies | Plasmid liquid; |
Described plasmid liquid is for containing the segmental DNA liquid of abl gene purpose, and its nucleotides sequence is classified SEQ ID NO:27 as.
The 4th optimal technical scheme of test kit of the present invention is: said test kit is the OD of the RNA that carries to the requirement that detects sample
260/ OD
2801.8~2.0.
The invention still further relates to the method for use of this test kit, may further comprise the steps:
(1) sample process: extract RNA nucleic acid; Negative control, positive control 1 are handled with sample simultaneously
Going bail for exists the sample 400 μ l in the Trizol, adds the 400ul chloroform, mixing, and room temperature was placed 5 minutes; Centrifugal 10 minutes of 15000rpm, colourless supernatant is drawn in centrifugal back, adds isopyknic buffer RLT, mixing,
Concrete steps are following:
5. going bail for exists the sample 400 μ l in the Trizol, adds 400 μ l chloroforms, mixing, and room temperature was placed 5 minutes; Centrifugal 10 minutes of 15000rpm, colourless supernatant is drawn in centrifugal back;
6. the Virahol that in above-mentioned supernatant, adds the equal-volume precooling, put upside down mixing after room temperature placed 10 minutes; Centrifugal 10 minutes of 15000rpm inhales and abandons supernatant;
7. in above-mentioned centrifuge tube, add 70% ethanol of 300 μ l precoolings, centrifugal 5 minutes of 15000rpm inhales and abandons supernatant; Room temperature 10 minutes makes the ethanol volatilization;
8. add 200ul DEPC-ddH
2The dissolving of O mixing is with this template as relevant PCR reaction.
(2) amplifing reagent is prepared:
Take-off pipe 1~7 from test kit, behind room temperature thawing and the vibration mixing, and of short duration centrifugal 1~8 second;
The preparation of sample PCR premixed liquid system:
Get RT-PCR reaction solution 18 μ l, add mixed enzyme solution I 2 μ l; Single sample preparation 4 pipes;
Get RT-PCR reaction solution 28 μ l, add mixed enzyme solution I 2 μ l; Single sample preparation 4 pipes;
Get RT-PCR reaction solution 38 μ l, add mixed enzyme solution I 2 μ l; Single sample preparation 4 pipes;
Get RT-confidential reference items PCR reaction solution 8 μ l, add mixed enzyme solution I 2 μ l; Single sample preparation 4 pipes;
Preparation with reference to article PCR premixed liquid system:
Get with reference to article PCR reaction solution 8 μ l, add mixed enzyme solution II 2 μ l; Preparation 4 pipes;
(3) application of sample:
Get 15 μ l from the sample to be tested pipe, join respectively in the PCR pipe that sample PCR premixed liquid system is housed;
Get 15 μ l from positive control 1 pipe that extracting is good, join respectively in the PCR pipe that sample PCR premixed liquid system is housed;
Get 15 μ l from positive control 2 pipes, join respectively in the PCR pipe that sample PCR premixed liquid system is housed;
Get 15 μ l from the good negative control pipe of extracting, join respectively in the PCR pipe that sample PCR premixed liquid system is housed;
Add to the PCR pipe that is equipped with reference to article PCR premixed liquid system from getting 15 μ l respectively, cover tight Guan Gai, it is moved to detection zone with reference to article 1~4 pipe;
(4) pcr amplification:
ABI PRISM fluorescence PCR detection system amplification condition: 42 ℃, 30min; 94 ℃, 5min; (94 ℃, 15sec; 60 ℃, 60sec) 40 circulations; Reaction system is 25ul; , PCR circulation second collects fluorescent signal when going on foot 60 ℃; Sense channel is: FAM-TAMRA, and reference fluorescence is set at none;
StratagenePCR fluorescence detector amplification condition: 42 ℃, 30min; 94 ℃, 5min; (94 ℃, 45sec; 60 ℃, 80sec) 40 circulations; Reaction system is 25ul; , PCR circulation second collects fluorescent signal when going on foot 60 ℃; Sense channel is: FAM-TAMRA
(5) detect:
(1) confirm baseline: selecting 3~15 round-robin mean fluorecence signals is baseline;
(2) confirm threshold value: do not have at negative control under the situation of amplification, threshold setting is at the vertex of no amplification curve sample, and negative control do not detect, and confirms as initiation threshold;
(3) computingmachine is handled and analytical data automatically.
This law also relates to the authentication method of said test kit, may further comprise the steps:
(1) availability deciding:
Four C with reference to article
TValue is less than 36.0, and the absolute value of typical curve degree of fitting is judged to be effectively more than or equal to 0.9; Otherwise it is quantitatively invalid to be regarded as;
Table 4:
(2) result judges:
After amplification finishes, analyze with the typical curve that obtains, obtain the detectable level of internal control gene in each sample;
A. as sample internal control gene C
TBe worth≤36 o'clock:
If the correlation detection gene C of sample
TValue≤36, it is positive then to be reported as its correlation detection gene;
If the correlation detection gene C of sample
TValue>=38 or show " Undet ", it is negative or be lower than minimum detection limit then to be reported as its correlation detection gene;
If the correlation detection gene C of 36<sample
TValue<38 then needs this sample is strengthened the RNA amount of getting, detects again, in order to avoid because the RNA add-on is very few, and produce omission;
B. as sample internal control gene C
TWhen value>36 or demonstration " Undet ":
Have inhibition or RNA add-on not enough in the ability sample, suggestion is carried out the extracting of RNA again or is carried out collection of specimens again and strengthen the PCR experiment of being correlated with again after the RNA amount of getting;
Table 5:
Wherein, for the patient after the treatment, internal control gene RNA detectable level adopts 1 * 10
6Copies.
Do further explanation and explanation in the face of content of the present invention down:
The technical superiority of test kit of the present invention is: the contriver is from China's actual conditions; Invented the relevant fusion gene detection kit of a kind of white blood disease; The RNA amount of BCR-ABL, AML1-ETO and PML-RARa in the relevant fusion gene of white blood disease in this test kit ability qualitative detection people bone marrow prepare, thus white blood disease clinical diagnosis and medication instructed.
The primer and the probe that are used to detect the BCR-ABL fusion gene are:
Table 6:
Title | Sequence | Modify |
SEQ?ID?NO:1 | CTGGCCCAACGATGGCGA | Do not have |
SEQ?ID?NO:2 | TCCGCTGACCATCAATAAGGA | Do not have |
SEQ?ID?NO:3 | TGGAGGAGGTGGGCATCTAC | Do not have |
SEQ?ID?NO:4 | CACTCAGACCCTGAGGCTCAA | Do not have |
SEQ?ID?NO:5 | CCCTTCAGCGGCCAGTAGCATCTGA | 5’Fam,3’Tamara |
The primer and the probe that are used to detect the PML-RARa fusion gene are:
Table 7:
Title | Sequence | Modify |
SEQ?ID?NO:6 | TCTTCCTGCCCAACAGCAA | Do not have |
SEQ?ID?NO:7 | ACCTGGATGGACCGCCTAG | Do not have |
?SEQ?ID?NO:8 | CCGATGGCTTCGACGAGTT | Do not have |
?SEQ?ID?NO:9 | GCTTGTAGATGCGGGGTAGAG | Do not have |
?SEQ?ID?NO:10 | AGTGCCCAGCCCTCCCTCGC | 5’Fam,3’Tamara |
The primer and the probe that are used to detect the AML1-ETO fusion gene are:
Table 8:
Title | Sequence | Modify |
?SEQ?ID?NO:11 | CACCTACCACAGAGCCATCAAA | Do not have |
?SEQ?ID?NO:12 | ATCCACAGGTGAGTCTGGCATT | Do not have |
?SEQ?ID?NO:13 | AACCTCGAAATCGTACTGAGAAGCACTCCA | ?5’Fam,3’Tamara |
Wherein, the primer of confidential reference items reaction is:
Table 9:
Title | Sequence | Modify |
?SEQ?ID?NO:14 | TGGAGATAACACTCTAAGCATAACTAAAGGT | Do not have |
?SEQ?ID?NO:15 | GATGTAGTTGCTTGGGACCCA | Do not have |
?SEQ?ID?NO:16 | CCATTTTTGGTTTGGGCTTCACACCATT | 5’Fam,3’Tamara |
Primer with reference in the article PCR reaction solution is:
Table 10:
Title | Sequence | Modify |
?SEQ?ID?NO:17 | TGGAGATAACACTCTAAGCATAACTAAAGGT | Do not have |
?SEQ?ID?NO:18 | GATGTAGTTGCTTGGGACCCA | Do not have |
The nucleotides sequence of BCR-ABL gene fragment is classified as:
Table 11:
Title | The different genes type of fusion gene |
?SEQ?ID?NO:19 | BCR-ABL-190(ela2) |
?SEQ?ID?NO:20 | BCR-ABL-210(b2a2) |
?SEQ?ID?NO:21 | BCR-ABL-210(b3a2) |
?SEQ?ID?NO:22 | BCR-ABL-230(e19a2) |
The nucleotides sequence of PML-RARa gene fragment is classified as:
Table 12:
Title | The different genes type of fusion gene |
?SEQ?ID?NO:23 | PML-RARA-L |
?SEQ?ID?NO:24 | PML-RARA-S |
?SEQ?ID?NO:25 | PML-RARA-V |
The nucleotides sequence of AML1-ETO gene fragment is classified as:
Table 13:
Title | Fusion gene |
?SEQ?ID?NO:26 | AML1-ETO |
The segmental nucleotides sequence of abl gene is classified as:
Table 14:
Title | Fusion gene |
?SEQ?ID?NO:27 | Abl gene, gene order number is NM_005157.4 |
In technological design; The present invention optimizes the pcr amplification system; And consumption, reaction volume and the method for extracting of experiment sample be optimized; Guarantee extracting under the minimum prerequisite of patient's sample, farthest the transcript to relevant fusion gene in the leukemia patient marrow detects.Simultaneously, confirmed to adopt the amplification condition of different instruments, to enlarge the range of application of this test kit.
The present invention adopts quality control product that finished product is done Performance Detection, specificity Quality Control article coincidence rate 100%, i.e. detected result all negative (except that internal control gene); Accuracy Quality Control article coincidence rate 100%, promptly detected result is all positive; BCR-ABL, PML-RAR α, AML-ETO and internal control gene sensitivity all reach 100 copy levels.In addition, carry out accuracy experiment, CV value≤10% with the cell lysate that carries fusion genes.
The present invention has also carried out stability test to test kit, comprises conventional stability, the stability of uncapping and transportation stability test, has confirmed the validity period of test kit according to experimental result.
On this basis, also test kit of the present invention has been carried out clinical examination, and contrasted experiment with gold standard-chromosome karyotype analysis, the result shows that the yin and yang attribute coincidence rate is good, and lower limit of detectability reaches 100 copies.
Test kit of the present invention can assist carry out that clinical definite, regimen are confirmed, therapeutic evaluation and prognosis judge: can detect the BCR-ABL fusion gene among the CML of about 90%-95% (chronic myelocytic leukemia) patient; About 90% M2b type (acute M2b type granulocyte leukemia) patient can detect the AML1-ETO fusion gene; About APL (acute promyelocytic leukemia) leukaemic more than 90% can detect the PML-RARa fusion gene; Therefore the detection to these fusion genes helps clinical making a definite diagnosis CML, APL and patient M2b; Confirm suitable chemotherapy regimen, thereby carry out therapeutic evaluation and help the clinician to obtain the prognosis of patients information judged.
Test kit of the present invention also can be assisted and recurred detection: through chemotherapy or transplanting; Most patients can obtain clinical remission, but because the existence of minimum remaining focus (MRD), all patients are faced with the risk of recurrence; This test kit can effectively be monitored MRD; Help the clinician early stage intervention treatment to be carried out in recurrence, delay recurrence, make patient obtain a secular DFS phase in the molecular biology level.
Specific embodiment mode of the present invention is only made explanations to content of the present invention and is explained, does not limit content of the present invention.Agents useful for same is the commercial reagent, and used instrument is the conventional instrument in laboratory.
Embodiment
Embodiment 1
Table 15:
Wherein:
Contain in the RT-PCR reaction solution 1 of detection BCR-ABL fusion gene: 5 * Buffer liquid, 5 μ l; Each 0.25 μ l of the dNTPs of 10mmol/L; Each 0.12 μ l of the SEQ ID NO:1 of 50 μ mol/L~SEQ ID NO:5; 50 μ mol/L SEQ ID NO:50.1 μ l complement to 8 μ l with process water;
Table 16:
Title | Sequence | Modify |
SEQ?ID?NO:1 | CTGGCCCAACGATGGCGA | Do not have |
SEQ?ID?NO:2 | TCCGCTGACCATCAATAAGGA | Do not have |
SEQ?ID?NO:3 | TGGAGGAGGTGGGCATCTAC | Do not have |
SEQ?ID?NO:4 | CACTCAGACCCTGAGGCTCAA | Do not have |
SEQ?ID?NO:5 | CCCTTCAGCGGCCAGTAGCATCTGA | 5’Fam,3’Tamara |
Contain in the RT-PCR reaction solution 2 of detection PML-RARa fusion gene: 5 * Buffer liquid, 5 μ l; Each 0.25 μ l of the dNTPs of 10mmol/L; Each 0.12 μ l of the SEQ ID NO:6 of 50 μ mol/L~SEQ ID NO:10; 50 μ mol/L SEQ ID NO:10,0.1 μ l complements to 8 μ l with process water;
Table 17:
Title | Sequence | Modify |
?SEQ?ID?NO:6 | TCTTCCTGCCCAACAGCAA | Do not have |
?SEQ?ID?NO:7 | ACCTGGATGGACCGCCTAG | Do not have |
?SEQ?ID?NO:8 | CCGATGGCTTCGACGAGTT | Do not have |
?SEQ?ID?NO:9 | GCTTGTAGATGCGGGGTAGAG | Do not have |
?SEQ?ID?NO:10 | AGTGCCCAGCCCTCCCTCGC | ?5’Fam,3’Tamara |
The primer and the probe that are used for detecting the AML1-ETO fusion gene are for containing: 5 * Buffer liquid, 5 μ l; Each 0.25 μ l of the dNTPs of 10mmol/L; Each 0.12 μ l of the SEQ ID NO:11 of 50 μ mol/L~SEQ ID NO:12; 50 μ mol/L SEQ ID NO:130.1 μ l complement to 8 μ l with process water;
Table 18:
Title | Sequence | Modify |
?SEQ?ID?NO:11 | CACCTACCACAGAGCCATCAAA | Do not have |
?SEQ?ID?NO:12 | ATCCACAGGTGAGTCTGGCATT | Do not have |
?SEQ?ID?NO:13 | AACCTCGAAATCGTACTGAGAAGCACTCCA | 5’Fam,3’Tamara |
Contain in the RT confidential reference items PCR reaction solution: 5 * Buffer liquid, 5 μ l; Each 0.25 μ l of the dNTPs of 10mmol/L; Each 0.12 μ l of the SEQ ID NO:14 of 50 μ mol/L~SEQ ID NO:16,50 μ mol/L SEQ ID NO:16,0.1 μ l complements to 8 μ l with process water; Wherein, By the upstream primer shown in the SEQ ID NO:14, by the downstream primer shown in the SEQ ID NO:15, by the probe shown in the SEQ ID NO:16; Wherein 5 ' of the nucleotide sequence shown in SEQ ID NO:16 end has the Fam mark, and 3 ' end has the Tamara mark;
Table 19:
Title | Sequence | Modify |
SEQ?ID?NO:14 | TGGAGATAACACTCTAAGCATAACTAAAGGT | Do not have |
SEQ?ID?NO:15 | GATGTAGTTGCTTGGGACCCA | Do not have |
SEQ?ID?NO:16 | CCATTTTTGGTTTGGGCTTCACACCATT | 5’Fam,3’Tamara |
With reference to containing in the article PCR reaction solution: 5 * Buffer liquid, 5 μ l; Each 0.25 μ l of the dNTPs of 10mmol/L; Each 0.12 μ l of the SEQ ID NO:17 of 50 μ mol/L~SEQ ID NO:18,50 μ mol/L SEQ ID NO:160.1 μ l complement to 8 μ l with process water; Wherein, by the upstream primer shown in the SEQ ID NO:17, by the downstream primer shown in the SEQ ID NO:18;
Table 20:
Title | Sequence | Modify |
?SEQ?ID?NO:17 | TGGAGATAACACTCTAAGCATAACTAAAGGT | Do not have |
?SEQ?ID?NO:18 | GATGTAGTTGCTTGGGACCCA | Do not have |
Contain among the mixed enzyme solution I: the UNG enzyme 0.2ml of the Taq archaeal dna polymerase 0.4ml of 5U/ μ l, 200U/ μ l RT enzyme 0.5ml, 40U/ μ l RNasin0.25ml, 1U/ μ l and enzyme storage liquid 0.65ml enzyme mix, and are equipped with the 2ml enzyme solution.
Contain among the mixed enzyme solution II: the Taq archaeal dna polymerase 0.4ml of 5U/ μ l, the UNG enzyme 0.2ml of 1U/ μ l and enzyme storage liquid 0.65ml enzyme mix, and are equipped with the 2ml enzyme solution.
Contain K562, NB4 and Kasumi cell lysate in the positive control 1, concentration is 2.5 * 10
3Cells/ml; Described positive control 2 is for containing the segmental four kinds of plasmids of BCR-ABL, PML-RARa, AML1-ETO and abl gene purpose respectively, and its nucleotide sequence is respectively SEQ ID NO:19~SEQ ID NO:27, and concentration is 1pg/m; Wherein, the K562 cell lysate is that BCR-ABL fusion gene male K562 cell lysate, NB4 cell lysate PML-RARa fusion gene male NB4 cell lysate, Kasumi cell lysate are AML1-ETO fusion gene male Kasumi cell lysate.
Contain in the positive control 2: 100pg/ml contains the segmental four kinds of plasmids of BCR-ABL, PML-RARa, AML1-ETO and abl gene purpose, with the dilution of Trziol liquid with 100 times; Wherein,
The nucleotides sequence of BCR-ABL gene fragment is classified as:
Table 21:
Title | The different genes type of fusion gene |
?SEQ?ID?NO:19 | BCR-ABL-190(ela2) |
?SEQ?ID?NO:20 | BCR-ABL-210(b2a2) |
?SEQ?ID?NO:21 | BCR-ABL-210(b3a2) |
?SEQ?ID?NO:22 | BCR-ABL-230(e19a2) |
The nucleotides sequence of PML-RARa gene fragment is classified as:
Table 22:
Title | The different genes type of fusion gene |
SEQ?ID?NO:23 | PML-RARA-L |
SEQ?ID?NO:24 | PML-RARA-S |
SEQ?ID?NO:25 | PML-RARA-V |
The nucleotides sequence of AML1-ETO gene fragment is classified as:
Table 23:
Title | Fusion gene |
?SEQ?ID?NO:26 | AML1-ETO |
The segmental nucleotides sequence of abl gene is classified as:
Table 24:
Title | Fusion gene |
?SEQ?ID?NO:27 | Abl gene, gene order number is NM_005157.4 |
Embodiment 2: adopt the test kit of embodiment 1 that sample is detected.
1, sample process: sample 1~10 adopts RNA to extract test kit and extracts RNA nucleic acid; The OD of the RNA that carries
260/ OD
2801.8~2.0.The RNA suggestion of having extracted detects immediately, otherwise in preserving below-80 ℃; The RNA that extracting is good adds the dissolving of 200ul RNeas-Free water mixing, with the template of this treatment solution as relevant PCR reaction;
2, amplifing reagent is prepared:
Take-off pipe 1~7 from test kit, behind room temperature thawing and the vibration mixing, and of short duration centrifugal 1~8 second;
The preparation of sample PCR premixed liquid system:
Get RT-PCR reaction solution 1 8ul, add mixed enzyme solution I 2ul; Single sample preparation 4 pipes;
Get RT-PCR reaction solution 2 8ul, add mixed enzyme solution I 2ul; Single sample preparation 4 pipes;
Get RT-PCR reaction solution 3 8ul, add mixed enzyme solution I 2ul; Single sample preparation 4 pipes;
Get RT-confidential reference items PCR reaction solution 8ul, add mixed enzyme solution I 2ul; Single sample preparation 4 pipes;
Preparation with reference to article PCR premixed liquid system:
Get with reference to article PCR reaction solution 8ul, add mixed enzyme solution II 2ul; Preparation 4 pipes;
3, application of sample:
Get 15ul from the sample to be tested pipe, join respectively in the PCR pipe that sample PCR premixed liquid system is housed;
Get 15ul from positive control 1 pipe, join respectively in the PCR pipe that sample PCR premixed liquid system is housed;
Get 15ul from positive control 2 pipes, join respectively in the PCR pipe that sample PCR premixed liquid system is housed;
Get 15ul from the negative control pipe, join respectively in the PCR pipe that sample PCR premixed liquid system is housed;
Add to the PCR pipe that is equipped with reference to article PCR premixed liquid system from getting 15ul respectively, cover tight Guan Gai, it is moved to detection zone with reference to article 1~4 pipe;
4, pcr amplification:
ABI PRISM fluorescence PCR detection system amplification condition: 42 ℃, 30min; 94 ℃, 5min; (94 ℃, 15sec; 60 ℃, 60sec) 40 circulations; Reaction system is 25ul; , PCR circulation second collects fluorescent signal when going on foot 60 ℃; Sense channel is: FAM-TAMRA, and reference fluorescence is set at none;
StratagenePCR fluorescence detector amplification condition: 42 ℃, 30min; 94 ℃, 5min; (94 ℃, 45sec; 60 ℃, 80sec) 40 circulations; Reaction system is 25ul; , PCR circulation second collects fluorescent signal when going on foot 60 ℃; Sense channel is: FAM-TAMRA;
5, detect
(1) confirming of baseline: it is baseline that software default is set 3-15 round-robin mean fluorecence signal.In experiment, general trade-off curve fluctuation is less, and that more stable section is as baseline, and the user can take the circumstances into consideration adjustment voluntarily according to practical situation.Starting point will be avoided beginning several cycles because the signal that high temperature causes increases, and is located at signal and has dropped to the background height and can keep place stably, and terminal point will be avoided covering signal and begin that the place that rises appreciably is arranged.According to the difference of empirical curve tendency, general start value can be chosen between the 3-12; The stop value is selected can 8 at interval be principle more than the circulation preferably between the Origin And Destination, better to satisfy the mathematics requirement of statistical baseline standard deviation.
(2) determines the threshold value: negative control, no amplification of the case, the threshold value is set in the absence of the amplification curve the highest point of the sample, that is higher than the no amplification growth curve (i.e. in the result of "Component" column no inflection point) the highest point, and the principle of the negative control was not detected, determine the starting threshold.
(3) note: different reaction solutions is analyzed after should distinguishing the baseline of confirming separately separately and threshold value more separately.
Computingmachine is handled and analytical data automatically.
Availability deciding:
Four C with reference to article
TValue is less than 36.0, and the absolute value of typical curve degree of fitting is judged to be effectively more than or equal to 0.9; Otherwise it is quantitatively invalid to be regarded as;
Table 25:
B, result judge:
After amplification finishes, analyze with the typical curve that obtains, obtain the detectable level of internal control gene in each sample;
A, as sample internal control gene C
TBe worth≤36 o'clock:
If the correlation detection gene C of sample
TValue≤36, it is positive then to be reported as its correlation detection gene;
If the correlation detection gene C of sample
TValue>=38 or show " Undet ", it is negative or be lower than minimum detection limit then to be reported as its correlation detection gene;
If the correlation detection gene C of 36<sample
TValue<38 then needs this sample is strengthened the RNA amount of getting, detects again, in order to avoid because the RNA add-on is very few, and produce omission;
B, as sample internal control gene C
TWhen value>36 or demonstration " Undet ":
Have inhibition or RNA add-on not enough in the ability sample, suggestion is carried out the extracting of RNA again or is carried out collection of specimens again and strengthen the PCR experiment of being correlated with again after the RNA amount of getting;
Table 26:
It is as shown in the table for experimental result:
Table 27:
Claims (9)
1. a primer and probe that detects the relevant fusion gene of white blood disease, wherein, the nucleotides sequence of said primer and probe is classified as:
(1) primer and the probe that is used to detect the BCR-ABL fusion gene is for by the upstream primer F1 shown in the SEQ ID NO:1; By the upstream primer F2 shown in the SEQ ID NO:2; By the upstream primer F3 shown in the SEQ ID NO:3, by the downstream primer shown in the SEQ ID NO:4, by the probe shown in the SEQ ID NO:5; Wherein 5 ' of the nucleotide sequence shown in SEQ ID NO:5 end has the Fam mark, and 3 ' end has the Tamara mark;
(2) primer and the probe that are used to detect the PML-RARa fusion gene are: by the upstream primer F1 shown in the SEQ ID NO:6; By the upstream primer F2 shown in the SEQ ID NO:7; By the upstream primer F3 shown in the SEQ ID NO:8, by the downstream primer shown in the SEQ ID NO:9, by the probe shown in the SEQ ID NO:10; Wherein 5 ' of the nucleotide sequence shown in SEQ ID NO:10 end has the Fam mark, and 3 ' end has the Tamara mark;
(3) primer and the probe that are used to detect the AML1-ETO fusion gene are: by the upstream primer F1 shown in the SEQ ID NO:11; By the downstream primer shown in the SEQ ID NO:12; By the probe shown in the SEQ ID NO:13; Wherein 5 ' of the nucleotide sequence shown in SEQ ID NO:13 end has the Fam mark, and 3 ' end has the Tamara mark.
2. one kind contains the primer of the relevant fusion gene of the said detection white blood disease of claim 1 and the test kit of probe; It is characterized in that; Consisting of of described test kit: described test kit comprises nucleic acid amplification reagent, reference substance and reference article, and wherein, described nucleic acid amplification reagent comprises:
3. test kit according to claim 2 is characterized in that,
Contain in the RT-PCR reaction solution 1 of detection BCR-ABL fusion gene: 5 * Buffer liquid, 5 μ l; Each 0.25 μ l of the dNTPs of 10mmol/L; Each 0.12 μ l of the SEQ ID NO:1 of 50 μ mol/L~SEQ ID NO:5; 50 μ mol/L SEQ ID NO:50.1 μ l complement to 8 μ l with process water;
Contain in the RT-PCR reaction solution 2 of detection PML-RARa fusion gene: 5 * Buffer liquid, 5 μ l; Each 0.25 μ l of the dNTPs of 10mmol/L; Each 0.12 μ l of the SEQ ID NO:6 of 50 μ mol/L~SEQ ID NO:10; 50 μ mol/L SEQ ID NO:100.1 μ l complement to 8 μ l with process water;
The primer and the probe that are used for detecting the AML1-ETO fusion gene are for containing: 5 * Buffer liquid, 5 μ l; Each 0.25 μ l of the dNTPs of 10mmol/L; Each 0.12 μ l of the SEQ ID NO:11 of 50 μ mol/L~SEQ ID NO:12; 50 μ mol/L SEQ ID NO:130.1 μ l complement to 8 μ l with process water;
Contain in the RT confidential reference items PCR reaction solution: 5 * Buffer liquid, 5 μ l; Each 0.25 μ l of the dNTPs of 10mmol/L; Each 0.12 μ l of the SEQ ID NO:14 of 50 μ mol/L~SEQ ID NO:16,50 μ mol/L SEQ ID NO:160.1 μ l complement to 8 μ l with process water;
With reference to containing in the article PCR reaction solution: 5 * Buffer liquid, 5 μ l; Each 0.25 μ l of the dNTPs of 10mmol/L; Each 0.12 μ l of the SEQ ID NO:17 of 50 μ mol/L~SEQ ID NO:18,50 μ mol/L SEQ ID NO:160.1 μ l complement to 8 μ l with process water.
4. test kit according to claim 2 is characterized in that, described reference substance is:
Contain K562, NB4 and Kasumi cell lysate in the described positive control 1, concentration is 2.5 * 10
3Cells/ml; Described positive control 2 is for containing the segmental four kinds of plasmids of BCR-ABL, PML-RARa, AML1-ETO and abl gene purpose respectively, and its nucleotide sequence is respectively SEQ ID NO:19~SEQ ID NO:27, and concentration is 1pg/ml.
5. test kit according to claim 2 is characterized in that, described reference article are:
Described plasmid liquid is for containing the segmental DNA liquid of abl gene purpose, and its nucleotides sequence is classified SEQ ID NO:27 as.
6. test kit according to claim 2 is characterized in that, said test kit is the OD of the RNA that carries to the requirement that detects sample
260/ OD
2801.8~2.0.
7. the method for use of test kit as claimed in claim 2 is characterized in that, may further comprise the steps:
(1) sample process: extract RNA nucleic acid; Negative control, positive control 1 are handled with sample simultaneously
Going bail for exists the sample 400 μ l in the Trizol, adds the 400ul chloroform, mixing, and room temperature was placed 5 minutes; Centrifugal 10 minutes of 15000rpm, colourless supernatant is drawn in centrifugal back, adds isopyknic buffer RLT, mixing,
Concrete steps are following:
1. going bail for exists the sample 400 μ l in the Trizol, adds 400 μ l chloroforms, mixing, and room temperature was placed 5 minutes; Centrifugal 10 minutes of 15000rpm, colourless supernatant is drawn in centrifugal back;
2. the Virahol that in above-mentioned supernatant, adds the equal-volume precooling, put upside down mixing after room temperature placed 10 minutes; Centrifugal 10 minutes of 15000rpm inhales and abandons supernatant;
3. in above-mentioned centrifuge tube, add 70% ethanol of 300 μ l precoolings, centrifugal 5 minutes of 15000rpm inhales and abandons supernatant; Room temperature 10 minutes makes the ethanol volatilization;
4. add 200ul DEPC-ddH
2The dissolving of O mixing is with this template as relevant PCR reaction.
(2) amplifing reagent is prepared:
Take-off pipe 1~7 from test kit, behind room temperature thawing and the vibration mixing, and of short duration centrifugal 1~8 second;
The preparation of sample PCR premixed liquid system:
Get RT-PCR reaction solution 18 μ l, add mixed enzyme solution I 2 μ l; Single sample preparation 4 pipes;
Get RT-PCR reaction solution 28 μ l, add mixed enzyme solution I 2 μ l; Single sample preparation 4 pipes;
Get RT-PCR reaction solution 38 μ l, add mixed enzyme solution I 2 μ l; Single sample preparation 4 pipes;
Get RT-confidential reference items PCR reaction solution 8 μ l, add mixed enzyme solution I 2 μ l; Single sample preparation 4 pipes;
Preparation with reference to article PCR premixed liquid system:
Get with reference to article PCR reaction solution 8 μ l, add mixed enzyme solution II 2 μ l; Preparation 4 pipes;
(3) application of sample:
Get 15 μ l from the sample to be tested pipe, join respectively in the PCR pipe that sample PCR premixed liquid system is housed;
Get 15 μ l from positive control 1 pipe that extracting is good, join respectively in the PCR pipe that sample PCR premixed liquid system is housed;
Get 15 μ l from positive control 2 pipes, join respectively in the PCR pipe that sample PCR premixed liquid system is housed;
Get 15 μ l from the good negative control pipe of extracting, join respectively in the PCR pipe that sample PCR premixed liquid system is housed;
Add to the PCR pipe that is equipped with reference to article PCR premixed liquid system from getting 15 μ l respectively, cover tight Guan Gai, it is moved to detection zone with reference to article 1~4 pipe;
(4) pcr amplification:
ABI PRISM fluorescence PCR detection system amplification condition: 42 ℃, 30min; 94 ℃, 5min; (94 ℃, 15sec; 60 ℃, 60sec) 40 circulations; Reaction system is 25ul; , PCR circulation second collects fluorescent signal when going on foot 60 ℃; Sense channel is: FAM-TAMRA, and reference fluorescence is set at none;
StratagenePCR fluorescence detector amplification condition: 42 ℃, 30min; 94 ℃, 5min; (94 ℃, 45sec; 60 ℃, 80sec) 40 circulations; Reaction system is 25ul; , PCR circulation second collects fluorescent signal when going on foot 60 ℃; Sense channel is: FAM-TAMRA;
(5) detect:
(1) confirm baseline: selecting 3~15 round-robin mean fluorecence signals is baseline;
(2) confirm threshold value: do not have at negative control under the situation of amplification, threshold setting is at the vertex of no amplification curve sample, and negative control do not detect, and confirms as initiation threshold;
(3) computingmachine is handled and analytical data automatically.
8. the authentication method of test kit as claimed in claim 2 is characterized in that, may further comprise the steps:
(1) availability deciding:
Four C with reference to article
TValue is less than 36.0, and the absolute value of typical curve degree of fitting is judged to be effectively more than or equal to 0.9; Otherwise it is quantitatively invalid to be regarded as;
(2) result judges:
After amplification finishes, analyze with the typical curve that obtains, obtain the detectable level of internal control gene in each sample;
A. as sample internal control gene C
TBe worth≤36 o'clock:
If the correlation detection gene C of sample
TValue≤36, it is positive then to be reported as its correlation detection gene;
If the correlation detection gene C of sample
TValue>=38 or show " Undet ", it is negative or be lower than minimum detection limit then to be reported as its correlation detection gene;
If the correlation detection gene C of 36<sample
TValue<38 then needs this sample is strengthened the RNA amount of getting, detects again, in order to avoid because the RNA add-on is very few, and produce omission;
B. as sample internal control gene C
TWhen value>36 or demonstration " Undet ":
Have inhibition or RNA add-on not enough in the ability sample, suggestion is carried out the extracting of RNA again or is carried out collection of specimens again and strengthen the PCR experiment of being correlated with again after the RNA amount of getting;
9. the authentication method of test kit as claimed in claim 2 is characterized in that, may further comprise the steps: for the patient after the treatment, internal control gene RNA detectable level adopts 1 * 10
6Copies.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210327547.3A CN102827937B (en) | 2012-09-06 | 2012-09-06 | Primer and probe for detecting relative fusion genes of leukemia and kit of primer and probe |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210327547.3A CN102827937B (en) | 2012-09-06 | 2012-09-06 | Primer and probe for detecting relative fusion genes of leukemia and kit of primer and probe |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102827937A true CN102827937A (en) | 2012-12-19 |
CN102827937B CN102827937B (en) | 2014-03-19 |
Family
ID=47331244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210327547.3A Active CN102827937B (en) | 2012-09-06 | 2012-09-06 | Primer and probe for detecting relative fusion genes of leukemia and kit of primer and probe |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102827937B (en) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103045590A (en) * | 2012-12-26 | 2013-04-17 | 武汉康圣达医学检验所有限公司 | Primer and method for detecting drug-resistant mutation point in BCR/ABL fusion gene ABL kinase zone by using same |
WO2014042497A1 (en) * | 2012-09-13 | 2014-03-20 | Mascir (Moroccan Foundation For Advanced Science, Research And Innovation) | Probes and primers for detecting the bcr-abl gene in a duplex reaction |
CN104178557A (en) * | 2013-05-28 | 2014-12-03 | 上海生物芯片有限公司 | Detection method for leukemia fusion genes, primers, probes and gene chip thereof |
CN104328210A (en) * | 2014-11-24 | 2015-02-04 | 山东省医学科学院基础医学研究所 | Primer and kit of loop-mediated isothermal amplification detection method of AML1/ETO fusion gene |
CN104561331A (en) * | 2015-01-21 | 2015-04-29 | 苏州云泰生物医药科技有限公司 | Primer and probe for detecting leukemia-related fusion gene and kit of primer |
WO2015060703A3 (en) * | 2013-10-10 | 2015-08-13 | Moroccan Foundation For Advanced Science, Innovation & Research (Mascir) | Kit for diagnosing chronic myeloid leukaemia in a multiplex reaction and applications of same to monitor the treatment and the residual disease |
CN106434983A (en) * | 2016-11-25 | 2017-02-22 | 徐州医科大学 | Primers and probe for detecting PML-RARA (promyelocytic leukemia and retinoic acid receptor alpha) gene mutation based on double-amplification refractory mutation system PCR (polymerase chain reaction), and their application |
CN106701957A (en) * | 2017-01-12 | 2017-05-24 | 广州蓝吉生物技术有限公司 | Kit for detecting fusion gene BCR-ABL (P210) mRNA expression |
CN107674914A (en) * | 2016-08-02 | 2018-02-09 | 熊术道 | One step single tube standard measure RT PCR detect the expression quantity of chronic myelogenous leukemia BCR ABL1 genes |
CN108977534A (en) * | 2018-03-30 | 2018-12-11 | 江苏省人民医院 | A kind of targeting sequencing kit and its application method and targeting sequencing approach |
CN109609632A (en) * | 2018-12-21 | 2019-04-12 | 北京优迅医学检验实验室有限公司 | Reagent, kit and the application of detection fusion gene |
CN110358825A (en) * | 2018-04-09 | 2019-10-22 | 苏州云泰生物医药科技有限公司 | Detect the kit and its application method of people BCR-ABL fusion |
CN110551817A (en) * | 2018-05-31 | 2019-12-10 | 苏州云泰生物医药科技有限公司 | Kit for detecting human WT1 fusion gene and use method thereof |
CN110551816A (en) * | 2018-05-31 | 2019-12-10 | 苏州云泰生物医药科技有限公司 | kit for detecting human PML-RARa fusion gene and use method thereof |
CN111166896A (en) * | 2020-01-19 | 2020-05-19 | 暨南大学 | Kit for treating chronic granulocytic leukemia based on berberine recruitment LRSAM1 degradation BCR-ABL1 |
CN112301129A (en) * | 2020-11-05 | 2021-02-02 | 深圳荻硕贝肯精准医学有限公司 | BCR-ABL fusion gene detection kit and BCR-ABL fusion gene detection method |
CN113403392A (en) * | 2021-02-20 | 2021-09-17 | 北京金则医学检验实验室有限公司 | Composition and kit for detecting tiny residual focus |
CN113943816A (en) * | 2021-12-03 | 2022-01-18 | 郑州思勤生物科技有限公司 | Nucleic acid compositions, kits and uses thereof |
CN114561473A (en) * | 2022-04-28 | 2022-05-31 | 南京世和基因生物技术股份有限公司 | Detection method of PML-RARA fusion gene mutation |
CN114592064A (en) * | 2022-04-01 | 2022-06-07 | 领航基因科技(杭州)有限公司 | Digital PCR kit for detecting multiple leukemia fusion genes |
CN115851924A (en) * | 2022-07-24 | 2023-03-28 | 济南金域医学检验中心有限公司 | Kit for detecting BCR-ABL fusion gene and application thereof |
CN117385039A (en) * | 2023-11-07 | 2024-01-12 | 上海市第一人民医院 | NAP1L1 MLLT10 fusion gene, primer probe composition, kit and application |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111850131B (en) * | 2020-08-26 | 2023-06-27 | 苏州卫生职业技术学院 | LAMP primer group, kit and detection method for detecting PML-RARA fusion gene |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1814791A (en) * | 2005-02-02 | 2006-08-09 | 镇江市第一人民医院 | Real-time quantitative PCR detecting human p190 bcr/abl transcript kit |
CN1995386A (en) * | 2006-08-22 | 2007-07-11 | 上海复星医药(集团)股份有限公司 | BCR-ABL gene fluorescence quantitative RT-PCR primer and probe and reagent kit |
CN102251031A (en) * | 2011-06-30 | 2011-11-23 | 北京思尔成生物技术有限公司 | TaqMan MGB probe real-time fluorescence PCR detection method for leukemia fusion genes, and special primers, probes and kit used by same |
-
2012
- 2012-09-06 CN CN201210327547.3A patent/CN102827937B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1814791A (en) * | 2005-02-02 | 2006-08-09 | 镇江市第一人民医院 | Real-time quantitative PCR detecting human p190 bcr/abl transcript kit |
CN1995386A (en) * | 2006-08-22 | 2007-07-11 | 上海复星医药(集团)股份有限公司 | BCR-ABL gene fluorescence quantitative RT-PCR primer and probe and reagent kit |
CN102251031A (en) * | 2011-06-30 | 2011-11-23 | 北京思尔成生物技术有限公司 | TaqMan MGB probe real-time fluorescence PCR detection method for leukemia fusion genes, and special primers, probes and kit used by same |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014042497A1 (en) * | 2012-09-13 | 2014-03-20 | Mascir (Moroccan Foundation For Advanced Science, Research And Innovation) | Probes and primers for detecting the bcr-abl gene in a duplex reaction |
CN103045590A (en) * | 2012-12-26 | 2013-04-17 | 武汉康圣达医学检验所有限公司 | Primer and method for detecting drug-resistant mutation point in BCR/ABL fusion gene ABL kinase zone by using same |
CN104178557A (en) * | 2013-05-28 | 2014-12-03 | 上海生物芯片有限公司 | Detection method for leukemia fusion genes, primers, probes and gene chip thereof |
CN104178557B (en) * | 2013-05-28 | 2018-10-26 | 上海生物芯片有限公司 | The detection method and its primer of leukemia fusion gene, probe and genetic chip |
WO2015060703A3 (en) * | 2013-10-10 | 2015-08-13 | Moroccan Foundation For Advanced Science, Innovation & Research (Mascir) | Kit for diagnosing chronic myeloid leukaemia in a multiplex reaction and applications of same to monitor the treatment and the residual disease |
CN104328210B (en) * | 2014-11-24 | 2016-06-22 | 山东省医学科学院基础医学研究所 | The primer of the loop-mediated isothermal amplification detection method of AML1/ETO fusion gene and test kit |
CN104328210A (en) * | 2014-11-24 | 2015-02-04 | 山东省医学科学院基础医学研究所 | Primer and kit of loop-mediated isothermal amplification detection method of AML1/ETO fusion gene |
CN104561331B (en) * | 2015-01-21 | 2016-08-31 | 苏州云泰生物医药科技有限公司 | A kind of primer detecting leukaemia correlation fusion gene and probe and kit thereof |
CN104561331A (en) * | 2015-01-21 | 2015-04-29 | 苏州云泰生物医药科技有限公司 | Primer and probe for detecting leukemia-related fusion gene and kit of primer |
CN107674914A (en) * | 2016-08-02 | 2018-02-09 | 熊术道 | One step single tube standard measure RT PCR detect the expression quantity of chronic myelogenous leukemia BCR ABL1 genes |
CN106434983B (en) * | 2016-11-25 | 2019-07-09 | 徐州医科大学 | Primer, probe and application based on dual amplification refractory mutation system PCR detection PML-RARA gene mutation |
CN106434983A (en) * | 2016-11-25 | 2017-02-22 | 徐州医科大学 | Primers and probe for detecting PML-RARA (promyelocytic leukemia and retinoic acid receptor alpha) gene mutation based on double-amplification refractory mutation system PCR (polymerase chain reaction), and their application |
CN106701957A (en) * | 2017-01-12 | 2017-05-24 | 广州蓝吉生物技术有限公司 | Kit for detecting fusion gene BCR-ABL (P210) mRNA expression |
CN108977534A (en) * | 2018-03-30 | 2018-12-11 | 江苏省人民医院 | A kind of targeting sequencing kit and its application method and targeting sequencing approach |
CN110358825A (en) * | 2018-04-09 | 2019-10-22 | 苏州云泰生物医药科技有限公司 | Detect the kit and its application method of people BCR-ABL fusion |
CN110551817A (en) * | 2018-05-31 | 2019-12-10 | 苏州云泰生物医药科技有限公司 | Kit for detecting human WT1 fusion gene and use method thereof |
CN110551816A (en) * | 2018-05-31 | 2019-12-10 | 苏州云泰生物医药科技有限公司 | kit for detecting human PML-RARa fusion gene and use method thereof |
CN109609632A (en) * | 2018-12-21 | 2019-04-12 | 北京优迅医学检验实验室有限公司 | Reagent, kit and the application of detection fusion gene |
CN111166896B (en) * | 2020-01-19 | 2024-03-29 | 暨南大学 | Kit for treating chronic granulocytic leukemia based on berberine recruitment LRSAM1 degradation BCR-ABL1 |
CN111166896A (en) * | 2020-01-19 | 2020-05-19 | 暨南大学 | Kit for treating chronic granulocytic leukemia based on berberine recruitment LRSAM1 degradation BCR-ABL1 |
CN112301129A (en) * | 2020-11-05 | 2021-02-02 | 深圳荻硕贝肯精准医学有限公司 | BCR-ABL fusion gene detection kit and BCR-ABL fusion gene detection method |
CN113403392A (en) * | 2021-02-20 | 2021-09-17 | 北京金则医学检验实验室有限公司 | Composition and kit for detecting tiny residual focus |
CN113943816A (en) * | 2021-12-03 | 2022-01-18 | 郑州思勤生物科技有限公司 | Nucleic acid compositions, kits and uses thereof |
CN114592064A (en) * | 2022-04-01 | 2022-06-07 | 领航基因科技(杭州)有限公司 | Digital PCR kit for detecting multiple leukemia fusion genes |
CN114561473A (en) * | 2022-04-28 | 2022-05-31 | 南京世和基因生物技术股份有限公司 | Detection method of PML-RARA fusion gene mutation |
CN115851924A (en) * | 2022-07-24 | 2023-03-28 | 济南金域医学检验中心有限公司 | Kit for detecting BCR-ABL fusion gene and application thereof |
CN117385039A (en) * | 2023-11-07 | 2024-01-12 | 上海市第一人民医院 | NAP1L1 MLLT10 fusion gene, primer probe composition, kit and application |
Also Published As
Publication number | Publication date |
---|---|
CN102827937B (en) | 2014-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102827937B (en) | Primer and probe for detecting relative fusion genes of leukemia and kit of primer and probe | |
CN104561331B (en) | A kind of primer detecting leukaemia correlation fusion gene and probe and kit thereof | |
CN103403181B (en) | NcRNA and application thereof | |
CN106148529B (en) | LncRNA marker related to gastric cancer, special detection primer, detection method, kit and application thereof | |
CN102586401A (en) | Method and kit for detecting mutation of BRAF gene of human colorectal cancer | |
CN104372102A (en) | Reagent kit used for testing PIK3CA (phosphatidylinositol-4,5-bisphosphate3-kinase, catalytic subunit alpha) gene mutations | |
Ben Lassoued et al. | Minimal residual disease testing in hematologic malignancies and solid cancer | |
CN107988369A (en) | Kit that is a kind of while detecting 45 mutational sites of Human epidermal growth factor receptor gene | |
CN108277263A (en) | A kind of the primer combination of probe object and its detection method of detection BRAF gene V600E | |
CN112680522B (en) | Kit for detecting bladder cancer | |
CN104531881A (en) | Fluorescence PCR detection kit for human K-RAS gene mutation | |
CN106434874A (en) | Droplet PCR (Polymerase Chain Reaction) kit for detecting mutation of human KRAS gene | |
CN102912018B (en) | Kit for detecting expression index of mRNA (messager Ribose Nucleic Acid) of WT1 (Wilms Tumor 1) gene | |
CN103074431A (en) | Special primer, kit and method for testing minRNA-128 in colorectal cancer serum | |
CN112646864A (en) | Primer, probe, kit and detection method for detecting ESR1 gene expression | |
CN102925575B (en) | Kit for detecting protein expression indexes of test equipment list-acute myelogenous leukemia1 (TEL-AML1) fusion gene messenger ribonucleic acid (mRNA) | |
CN110863054A (en) | Digital PCR detection kit for detecting mutation of gene mutation high-incidence region and method thereof | |
CN106636440B (en) | Blood plasma microRNAs is used to prepare the purposes of the diagnostic reagent of patients with lung adenocarcinoma in sieving and diagnosis male population | |
CN110358825A (en) | Detect the kit and its application method of people BCR-ABL fusion | |
CN109112187A (en) | A kind of kit for the ARMS-ddPCR detection gene mutation that closing probe mediates | |
CN103184274A (en) | EGFR mutation detection kit based on LDR technology | |
Chen et al. | Potential use of transrenal DNA for non-invasive monitoring and prognosis of colorectal cancer | |
CN102965433A (en) | Kit for detecting mRNA expression quantity of M BCR fusion gene | |
CN114774539B (en) | Primer, probe and kit for detecting colorectal cancer polygene variation and application of primer, probe and kit | |
CN108315427A (en) | A kind of the primer combination of probe object and its detection method of detection tumour KRAS genes G12D |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |